Get the Stockscreener App
6.04
9.58%
-0.64
Agenus Inc stock is traded at $6.04, with a volume of 1.03M.
It is down -9.58% in the last 24 hours and down -16.23% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$6.68
Open:
$6.65
24h Volume:
1.03M
Relative Volume:
1.03
Market Cap:
$272.78M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
3.6178
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
-21.25%
1M Performance:
-16.23%
6M Performance:
+30.17%
1Y Performance:
+51.38%
1-Day Range:
$6.00
$6.70
1-Week Range:
$6.00
$7.66
52-Week Range:
$2.71
$10.31
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
6.04 | 272.78M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-26 | Initiated | Rodman & Renshaw | Buy |
| Sep-18-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-13-26 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference - BioSpace
Agenus Inc. (AGEN) options chain - Yahoo Finance UK
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance Singapore
Agenus Inc. (AGEN) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination - Yahoo Finance
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - 뉴스와이어
Agenus (AGEN) Reports Durable 3-Year Ovarian Cancer Trial Results Amid Valuation and Financial Challenges - GuruFocus
Agenus Inc. (AGEN) latest stock news and headlines - Yahoo Finance UK
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 - BioSpace
Director Wright acquires 1.18K units of future Agenus (AGEN) shares at $6.893 each. - Stock Titan
A director acquires 4,443 Agenus (AGEN) shares through an election to receive fees in stock. - Stock Titan
Joe Cotton’s Stock Pick of the Week: A risky biotech stock, Agenus, a promising colorectal cancer drug - NKyTribune
Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock SoaringBut Caution Advised - Seeking Alpha
Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN) - Seeking Alpha
Agenus Shares Rise After Chardan Initiates Coverage at Buy - marketscreener.com
AGEN Initiates Coverage On Agenus by Rodman & Renshaw -- Rating Buy - GuruFocus
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com Nigeria
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - easternprogress.com
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Dura - The National Law Review
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
New Agenus (AGEN) director receives 7,500 stock options - Stock Titan
Spouse-held shares feature in Agenus (AGEN) director's stake - Stock Titan
September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant ImmunotherapyAgenus - Oncodaily
Agenus Inc Share PriceAGEN, RNS News, Articles, Quotes, & Charts (NASDAQ:AGEN) - Proactive financial news
AGEN S-3 FilingsAgenus Inc. SEC S-3 - stocktitan.net
Agenus Inc. (AGEN) Shareholder/Analyst CallSlideshow (NASDAQ:AGEN) 2026-09-11 - Seeking Alpha
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - BioSpace
Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - New Castle News
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Business Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus Company Profile & Introduction - moomoo.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Agenus to Participate in Upcoming September Investor Conferences - Yahoo Finance
Immigrant Entrepreneur Garo H. Armen Of Agenus Inc. Riccardo Braschi (I0EURkuuPl) - Mshale
New Phase 2 NEST Results Support Neoadjuvant BOT+BAL in Colon Cancer – Agenus - Oncodaily
Agenus reports survival data for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Yahoo Finance
Agenus reports survival data for colorectal cancer treatment - investing.com
Agenus Inc: Shareholders Revolt Over Executive Pay! My Thoughts. Tampa Bay Rays (VzxHMd1TNP) - Mshale
Agenus Inc.AGEN Stock Chart Technical Analysis For 09-21-2020 Sporting Cp (0os72ROBex) - Mshale
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Yahoo Finance
Agenus Reports No Recurrences and Deep Pathologic Responses With Neoadjuvant BOT+BAL in Resectable Colon Cancer - Oncodaily
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (9cYwfB9Crl) - Mshale
Agenus | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks Donald Gibb (Gf1su3sDdD) - Mshale
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):